The Zacks Analyst Blog Highlights: Vertex Pharmaceuticals, Market Vectors Biotech ETF, iShares Nasdaq Biotechnology ETF, First Trust NYSE Arca Biotechnology Index Fund, PowerShares Dynamic Biotechnology & Genome Portfolio and SPDR S&P Biotech

Zacks

For Immediate Release
 
Chicago, IL – June 26, 2014 – Zacks.com announces the list of stocks featured in the Analyst Blog. Every day the Zacks Equity Research analysts discuss the latest news and events impacting stocks and the financial markets. Stocks recently featured in the blog include the Vertex Pharmaceuticals (VRTX-Free Report), Market Vectors Biotech ETF (BBH-Free Report)iShares Nasdaq Biotechnology ETF (IBB-Free Report), First Trust NYSE Arca Biotechnology Index Fund (FBT-Free Report), PowerShares Dynamic Biotechnology & Genome Portfolio (PBE-Free Report) and SPDR S&P Biotech ETF (XBI-Free Report).
 
Today, Zacks is promoting its ''Buy'' stock recommendations. Get #1Stock of the Day pick for free.

Here are highlights from Wednesday’s Analyst Blog:

Vertex Pharma Pushes Biotech ETFs Higher

Vertex Pharmaceuticals (VRTX-Free Report) was a star performer in Tuesday’s trading session, as the stock skyrocketed over 48%, representing the biggest gain since April 2003. The massive gain for this biotech firm came from promising results from two crucial Phase III trials of a cystic fibrosis treatment.
 
The results showed that a combination regimen of lumacaftor and ivacaftor (Kalydeco) could successfully treat certain symptoms of cystic fibrosis. The drug combination, when compared with a placebo, improves lung function of the patient by 2.6–4% and reduces pulmonary flare-ups, which can lead to hospitalization (read: A Comprehensive Guide to Biotech ETFs).
 
Close to 30,000 Americans and 75,000 people globally above the age of 12 suffer from genetic cystic fibrosis, according to various sources. This is a rare and deadly lung disease that hampers the flow of salt and water into and out of the cell in a number of organs, including lungs. The disease builds mucus in the lungs, which causes infections and lung damage.
 
The approval for the treatment in the U.S. and the European Union is expected in the fourth quarter based on the final trials. The treatment, if successful, could make Vertex a leader in treating cystic fibrosis.
 
Market Impact
 
With the potential to dominate this market, the extremely positive trial results were well received by investors. The stock reached its highest level in 14 years to $98.80 on the day but closed a little lower at $93.53 on elevated volume of 11 times more than the average daily volume.  
 
The news also led to a surge in biotech ETFs – Market Vectors Biotech ETF (BBH-Free Report)iShares Nasdaq Biotechnology ETF (IBB-Free Report) and First Trust NYSE Arca Biotechnology Index Fund (FBT-Free Report) which gained 1.22%, 1.02% and 0.99%, respectively, on Tuesday trading session (read: Any Survivors from the Biotech ETF Meltdown?).
 
BBH in Focus
 
This fund tracks the Market Vectors US Listed Biotech 25 Index, holding 26 securities with a tilt toward large cap and growth stocks. Vertex Pharma takes the ninth position in the basket with a 5.53% share. The product has so far amassed $501.6 million in its asset base while charging 35 bps in annual fees.
 
IBB in Focus
 
This fund provides exposure to 123 firms by tracking the Nasdaq Biotechnology Index with Vertex taking up the eight position at 3.49%. Growth stocks are once again a big part of the portfolio with 86% of assets while large caps account for 58% share. IBB is the most popular fund is the biotech space with AUM of $5.2 billion and average daily volume of over 1.8 million shares. Expense ratio came in at 0.48% (read: How Will Biotechnology ETFs Finish Out the Year?).
 
FBT in Focus
 
This fund follows the NYSE Arca Biotechnology Index and holds about 20 securities in its basket. Of these firms, VRTX occupies the second position with 6.47% allocation. The ETF is spread across various market caps – 42% in mid caps, 40% in large caps and rest in small caps with a tilt toward growth stocks at 73%. The fund manages a $1.3 billion in its asset base and charges 60 bps in annual fees. Volume is moderate as it exchanges 192,000 shares a day on average.
 
Bottom Line
 
The upward trend in these products are likely to continue the coming months given their Zacks ETF Rank of 1 or ‘Strong Buy’ rating with High risk outlook (see: all the Healthcare ETFs here).
 
In fact, the three ETFs have clearly outpaced the other products in the biotech space in the last trading session. PowerShares Dynamic Biotechnology & Genome Portfolio (PBE-Free Report) and SPDR S&P Biotech ETF (XBI-Free Report) lost 0.8% and 0.3%, respectively, on the day. This is because these products have little or no exposure to Vertex Pharma.

Today, Zacks is promoting its ''Buy'' stock recommendations. Get #1Stock of the Day pick for free.
 
About Zacks Equity Research

Zacks Equity Research provides the best of quantitative and qualitative analysis to help investors know what stocks to buy and which to sell for the long-term.

Continuous coverage is provided for a universe of 1,150 publicly traded stocks. Our analysts are organized by industry which gives them keen insights to developments that affect company profits and stock performance. Recommendations and target prices are six-month time horizons.

Zacks "Profit from the Pros" e-mail newsletter provides highlights of the latest analysis from Zacks Equity Research. Subscribe to this free newsletter today.

About Zacks

Zacks.com is a property of Zacks Investment Research, Inc., which was formed in 1978. The later formation of the Zacks Rank, a proprietary stock picking system; continues to outperform the market by nearly a 3 to 1 margin. The best way to unlock the profitable stock recommendations and market insights of Zacks Investment Research is through our free daily email newsletter; Profit from the Pros.  In short, it's your steady flow of Profitable ideas GUARANTEED to be worth your time! Register for your free subscription to Profit from the Pros.
 
Get the full Report on VRTX - FREE
Get the full Report on BBH - FREE
Get the full Report on IBB - FREE
Get the full Report on FBT - FREE
Get the full Report on PBE - FREE
Get the full Report on XBI - FREE
 
Follow us on Twitter: http://twitter.com/zacksresearch

Join us on Facebook: http://www.facebook.com/home.php#/pages/Zacks-Investment-Research/57553657748?ref=ts

Zacks Investment Research is under common control with affiliated entities (including a broker-dealer and an investment adviser), which may engage in transactions involving the foregoing securities for the clients of such affiliates.
 
Media Contact
Zacks Investment Research
800-767-3771 ext. 9339
support@zacks.com
http://www.zacks.com

 
Past performance is no guarantee of future results. Inherent in any investment is the potential for loss. This material is being provided for informational purposes only and nothing herein constitutes investment, legal, accounting or tax advice, or a recommendation to buy, sell or hold a security. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. It should not be assumed that any investments in securities, companies, sectors or markets identified and described were or will be profitable. All information is current as of the date of herein and is subject to change without notice. Any views or opinions expressed may not reflect those of the firm as a whole. Zacks Investment Research does not engage in investment banking, market making or asset management activities of any securities. These returns are from hypothetical portfolios consisting of stocks with Zacks Rank = 1 that were rebalanced monthly with zero transaction costs. These are not the returns of actual portfolios of stocks. The S&P 500 is an unmanaged index. Visit http://www.zacks.com/performance for information about the performance numbers displayed in this press release.

Read the analyst report on VRTX

Read the analyst report on BBH

Read the analyst report on IBB

Read the analyst report on FBT

Read the analyst report on PBE

Read the analyst report on XBI


Zacks Investment Research

View Comments (0)